tbuckley/cabot-search huggingface dataset:
High-Dose Ifosfamide-Induced Exacerbation of Peripheral Neuropathy
Authors: S R Patel, A D Forman, R S Benjamin
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article High-Dose Ifosfamide-Induced Exacerbation of Peripheral Neuropathy Get access Shreyaskumar R. Patel, Shreyaskumar R. Patel * * Shreyaskumar R. Petel, M.D., The University of Taxes M. D. Anderson Cancer Center, Box 77, 1515 Holcombe Blvd., Houston. TX 77030. Search for other works by this author on: Oxford Academic PubMed Google Scholar Arthur D. Forman, Arthur D. Forman Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert S. Benjamin Robert S. Benjamin Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 4, 16 February 1994, Pages 305–306, https://doi.org/10.1093/jnci/86.4.305 Published: 16 February 1994 Article history Received: 05 October 1993 Revision received: 01 November 1993 Accepted: 02 November 1993 Published: 16 February 1994
FRI0527 Underlying diagnosis predicts patient-reported outcomes after revision total hip arthroplasty
Authors: J. A. Singh, D. Lewallen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Pain and function are the most important outcomes after hip arthroplasty. While focus has been on revision rates, less attention has been paid to factors that are associated with suboptimal patient-reported outcomes such as pain and function. <h3>Objectives</h3> To assess the association of underlying diagnosis with patient-reported outcomes (PROs) after revision total hip arthroplasty. <h3>Methods</h3> We used prospectively collected data from the Mayo Clinic Total Joint Registry, a large U.S. institutional registry, that collects pre- and post-operative pain and function outcomes using a validated Hip questionnaire in all patients who undergo THA at the Mayo Clinic. We used data on all revision THAs from 1993-2005 captured electronically in the registry. We used logistic regression to assess the odds of moderate-severe index hip pain and moderate-severe ADL limitations 2- and 5-years after revision THA. Odds ratios (OR) and 95% confidence intervals (CIs) are presented. <h3>Results</h3> The underlying diagnosis was loosening, wear or osteolysis in 73% and 75%; dislocation, bone or prosthesis fracture, instability or non-union in 17% and 15%; and failed prior arthroplasty with components removed or infection in 11% and 11%, respectively. In multivariable-adjusted analyses that included 15-additional variables including preoperative ADL limitations, compared to patients with loosening/wear/osteolysis, patients with dislocation/fracture/instability/non-union had OR of 2.2 (95% CI, 1.3-3.5; p=0.002) and those with failed prior arthroplasty/infection had OR of 1.6 (95% CI, 1.0-2.8; p=0.06). At 5-years, ORs were lower and differences were no longer significant Moderate-severe pain did not differ significantly by diagnosis, at 2- or 5-years in multivariable adjusted analyses, with one exception, i.e. failed prior arthroplasty/infection had a trend towards significance with odds ratio of 1.9 (95% CI, 0.9-3.8; p=0.07). <h3>Conclusions</h3> Underlying diagnosis is independently associated with ADL limitations, but not pain, at 2-years after revision THA. Patients should be informed of the risk of poorer outcomes based on their diagnosis. <h3>Disclosure of Interest</h3> J. Singh Grant/research support from: takeda, Savient, Consultant for: takeda, Savient, allergan, Ardea, Regeneron, Novartis, D. Lewallen: None Declared
A YOUNG FEMALE WITH ST ELEVATION MYOCARDIAL INFARCTION AND AN OCCLUDED LEFT ANTERIOR DESCENDING ARTERY SECONDARY TO SPONTANEOUS CORONARY DISSECTION: LESS IS MORE
Authors: Vladimir Lakhter, Casey Ling, Evan Klein, Cara Heller, Howard Cohen, Brian O'Murchu, Brian O'Neill, Anay Pradhan, Ravishankar Raman, Riyaz Bashir
Journal: Journal of the American College of Cardiology (2016)
SAT0100 Bone marrow OEDEMA is more associated with rapid radiographic progression than synovitis or bone erosion by using low field MRI in bio-naïve rheumatoid arthritis patients treated with adalimumab and methotrexate combination therapy
Authors: K. Katayama, T. Okubo, T. Sato, R. Fukai, N. Miyoshi, T. Matsuno
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rapid radiographic progression (RRP) has occurred in some rheumatoid arthritis (RA) patients regardless of any type of biological therapy. However, early diagnosis of RRP is still unknown. <h3>Objectives</h3> The aim of this study is to find predictive MRI findings for RRP in RA patients. <h3>Methods</h3> Twenty two RA patients, who treated for 1 year with Adalimumab (ADA) and methotrexate (MTX) combination therapy, were examined by radiography for both hands and feet using total Sharp-van der Heijde scoring (SHS) and compact MRI for both hands using cMRI score (cMRIS) (1) in low field MRI (0.3T) at baseline and 1 year after treatment. We analyzed to find the relationship between MRI and radiographic findings compared with RRP (SHS/y≥3) and non RRP (SHS/y &lt;3) group. <h3>Results</h3> Patients baseline demographics were: mean age: 60.1 year; RA disease duration: 8.4 year; baseline DAS28(ESR): 6.28; estimated ΔSHS/y: 13.7/y and HAQ-DI:1.9. At 1 year, 60.9% of patients achieved radiographic remission (ΔSHS/y &lt;0.5) and ΔSHS/y was -0.5 (ΔJSN/y: 0.96, ΔJEN/y: -1.54). The cMRI showed 46.8%, 70.9%, 22.7% and 39.8% improvement of cMRIS<i>synovitis</i>, cMRIS<i>oedema</i>, cMRIS<i>erosion</i> and cMRIS<i>erosion + synovitis + oedema</i>, respectively. Three patients were assessed for RRP group (n=3, SHS=6, 8 and 17, mean: 10.3). Other patients were assessed for non RRP group (n=19, -9≤SHS≤2: mean: -2.1). Radiographically, there were significant differences between two groups in ΔSHS/y and ΔJEN/y, (P&lt;0.01). In MRI, significant increase of cMRIS<i>oedema</i> at baseline (P&lt;0.05), cMRIS<i>oedema</i> at 1 year (P&lt;0.01) and significant decrease of percentage improvement of cMRIS<i>oedema</i> (P&lt;0.01), cMRIS<i>synovitis</i> (P&lt;0.05), cMRIS<i>erosion + synovitis + oedema</i> (P&lt;0.05) were observed in RRP group compared with non RRP group. These results showed that at baseline, bone marrow oedema in MRI was more predictive than synovitis (P=0.80, NS) or bone erosion (P=0.51, NS) as previously reported (2), and perpetuation of bone marrow edema was important for RRP at 1year. <h3>Conclusions</h3> In low field MRI, bone marrow oedema was more associated with occurrence of RRP than synovitis or bone erosion in bio-naïve RA patients during ADA and MTX combination therapy. <h3>References</h3> T.Suzuki et al. A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis. Mod.Rheumatol. 2009: 19. 358-365 F.Gandjbakhen et al. Bone marrow oedema predicts structual progression in 1-year follow up of 85 patients with RA in remission or with low disease activity with low-field MRI. Ann.Rheum.Dis.2011:70.2159-2162 <h3>Disclosure of Interest</h3> None Declared
PTH-155 The Hospital Admission Burden of Inflammatory Bowel Disease: A 10 Year Review from a District General Hospital
Authors: M W Johnson, K Lithgo, T Prouse, T Price
Journal: Gut (2013)

<h3>Introduction</h3> The National IBD Standards and IBD (Global Rating Score) Quality Improvement Programme have highlighted areas of our inflammatory bowel disease (IBD) service that need funding, in order to make the neccessary improvements. To facilitate this we set about establishing the total cost and demand of managing IBD patients in our local hospital, reviewing 4 key areas; the endoscopy, radiology, outpatients and hospital admissions services. Study Objectives: To assess the average length of stay (LOS) and total number of hospital admissions made by IBD patients over 10y. <h3>Methods</h3> The Luton &amp; Dunstable University Hospital has a database of 2680 local IBD patients. This is made up of 1425 patients with UC, 941 with Crohn’s, 118 with proctitis, 113 with IBD unspecified, 53 with radiation proctitis, 13 with diversion colitis, 10 with ileo-anal pouchitis and 7 with microscopic colitis. Using this database the hospital coding system was used to analyse the total number of hospital admissions made between 2001 and 2011 for these patients, and to which specialties they were being admitted. <h3>Results</h3> Over the course of 10 years the 2680 IBD patients made a total of 6385 hospital admissions. Of these, UC patients accounted for 2524 admissions, whilst the Crohn’s patients had a proportionally higher admission rate, accounting for 2504 admissions. The number of admissions per patient ranged from 1 to 134, and of those admitted they had a mean of 6.4 admissions each. These patients were being admitted by a range of specialties including 4361 by general medicine, 1260 by general surgery, 251 by elderly care, 103 by paediatrics, 101 by orthopaedics, 66 by urology, 29 by the ears, nose and throat team, 45 by obstetrics and gynaecology, 11 by medical oncology, 48 by haematology, 5 obstetrics, 32 by ophthalmology, 43 by the maxillary facial team, 4 by A+E, 1 by anaesthetic pain relief team, 24 by cardiology and 1 by dermatology. The type of admission ranged from being elective/planned admissions in 4457, A+E emergency admissions in 1,363, emergency admission from clinic in 116, emergency GP admissions in 420, and 9 patients transfers from other hospitals. <h3>Conclusion</h3> Over the 10 year period 1724/2680 (64%) of all the IBD patients required at least 1 hospital admission. On average this cohort of patients required a mean of 2.4 hospital admissions, with Crohn’s disease patients placing a greater demand on the hospital admission services (average = 2.66 admissions) as compared with the UC patients (average = 1.77). The average length of stay was 2.6 days (range = 1–278 days). Whilst it is clear that not all the hospital admissions were directly related to the underlying IBD, it is clear that there is a heavy demand placed on the local hospital admission services from this cohort of IBD patients. <h3>Disclosure of Interest</h3> None Declared.
GE-42 * INTEGRATED RADIOGRAPHIC AND PHYLOGENETIC CASE STUDY OF A PRIMARY AND CONTRALATERAL RECURRENT GLIOMA
Authors: R. Nagarajan, R. Barajas, T. Mazor, J. Phillips, J. Ma, C. Hong, B. Johnson, M. Dayal, S. Cha, J. Nakamura, M. Berger, S. Chang, F. Furnari, B. Taylor, J. Costello
Journal: Neuro-Oncology (2014)

Extensive neuropil invasion is a hallmark of glioma growth and a subset of tumors demonstrate recurrence in the contralateral hemisphere without a path of tumor spread detected by MR imaging. We used an integrated genomic and radiographic approach to study a patient with a right nonenhancing insular mass histologically diagnosed as IDH1/2 wild-type anaplastic astrocytoma (AA) and a punctate nonenhancing T2 hyperintense focus within the left middle frontal gyrus subcortical white matter. Follow-up MR imaging, six months after initiation of Temozolomide based chemoradiotherapy, demonstrated focal enhancement within the left middle frontal gyrus lesion. Six months later a rim enhancing centrally necrotic mass involving left frontal lobe white matter was observed and diagnosed as glioblastoma. Whole exome sequencing of both tumors and targeted Sanger sequencing of 7-9 samplings from each tumor identified a novel five amino acid in-frame insertion in the PTEN C2 domain in both tumors that potentially disrupts cell membrane interaction and activates phosphotidylinositol 3-kinase (PI3K) signaling. As wild-type PTEN inhibits cellular migration, this early PTEN mutation might also promote invasion and the seeding of metastatic foci remote from the initial tumor mass. The right insular AA harbored amplifications of EGFR, MDM4 and PDGFRA (amplified and mutated) that were not detected within the contralateral glioblastoma. Conversely, the glioblastoma acquired CDKN2A homozygous deletion, probable NF1 biallelic inactivation (mutation and heterozygous loss), and a second hit to PTEN (heterozygous loss). Thirty-six shared mutations (including PTEN) and two shared copy number alterations unequivocally indicate a common origin for these spatially and temporally separated tumors. Taken together, these integrated radiographic and genomic data strongly suggest that the cells seeding the left frontal lobe tumor migrated from the evolving right insular tumor at an early time point and then followed an independent evolutionary trajectory.
Genetic Screening for Hemophilia A (Classic Hemophilia) with a Polymorphic DNA Probe
Authors: Isabelle Oberle, Giovanna Camerino, Roland Heilig, Lelia Grunebaum, Jean-Pierre Cazenave, Calogero Crapanzano, Pier M. Mannucci, Jean-Louis Mandel
Journal: New England Journal of Medicine (1985)

We have developed a new method of screening for hemophilia A in families at risk for the disease. A DNA probe (St14) that detects a very polymorphic region on the human X chromosome has been shown to be closely linked to hemophilia A. We observed no recombination between the St14 locus and hemophilia A in 12 families studied. The odds in favor of linkage are 4.4 x 109 to 1 (lod score, 9.65). The 95 per cent confidence interval for the probability of a recombination between St14 and hemophilia A is 0 to 6.5 per cent. This DNA probe, which is informative in more than 90 per cent of families at risk of hemophilia A, can be used in conjunction with classic biologic assays to identify carriers with an accuracy of 96 per cent or more. If a small risk of misclassification due to crossover between the test and the disease loci is accepted, this DNA marker should allow first-trimester prenatal diagnosis of hemophilia A. Segregation analysis with St14 may thus represent a major improvement in genetic counseling for hemophilia A. (N Engl J Med 1985; 312:682–6.)
Imaging Seminal Vesiculitis with Tc-99m Ciprofloxacin
Authors: Wonsick Choe, Ji Kan Ryu, Won-Hong Kim, Moon-Hyun Chung, Jun-Kyu Suh
Journal: Clinical Nuclear Medicine (2003)

CHOE, WONSICK M.D., M.P.H.*; KAN RYU, JI M.D.†; KIM, WON-HONG M.D.‡; CHUNG, MOON-HYUN M.D.§; SUH, JUN-KYU M.D.† Author Information
Abstract 4047: TRIM32 facilitates cell growth, migration and anti-apoptosis
Authors: Satoshi Kano, Shigetsugu Hatakeyama, Satoshi Fukuda, Hiromitsu Hatakeyama
Journal: Cancer Research (2011)

Abstract Introduction: Tripartite motif (TRIM) proteins are characterized by the presence of a RING finger, one or two zinc-binding motifs named B-boxes and an associated coiled-coil region. Most TRIM proteins have been reported to have a role in the ubiquitination process. Furthermore, several TRIM family members are involved in various cellular processes such as transcriptional regulation, cell growth, apoptosis, development and oncogenesis. TRIM32 also has a RING-finger domain and functions as an E3-ubiquitin ligase. In the previous study, it has been reported that TRIM32 protein expression is elevated in a mouse skin carcinogenesis model and in human skin squamous cell carcinoma and TRIM32 mRNA expression is elevated in human head and neck squamous cell carcinoma. However, the involvement of TRIM32 in carcinogenesis has not been fully elucidated. In this study, we studied the function of TRIM32 in the progression of carcinogenesis. Methods: We established the cell lines overexpressed TRIM32 wild type and the deletion mutant of the RING-finger domain by the infection of retrovirus vectors. Using these cell lines, we analyzed the effect of TRIM32 on cell growth, transforming activity, cell motility and apoptosis induced by cisplatin. Additionally, we investigated whether siRNA for TRIM32 effects on these functions. Furthermore, we examined the expression level of TRIM32 protein in oral carcinoma samples using immunohistochemical method and analyzed the relationship between TRIM32 and clinical presentation. Results: Overexpression of TRIM32 promoted cell growth, transforming activity and cell motility, whereas a dominant negative mutant of TRIM32 lacking the RING-finger domain inhibited these effects. In addition, we found that TRIM32 suppressed apoptosis induced by cisplatin in HEp2 cell lines, originating from human laryngeal squamous cell carcinoma. In contrast, siRNA for TRIM32 suppressed cell proliferation, cell motility and anti-apoptosis. In clinical research, a high-expression group of TRIM32 presented more advanced stage (clinical stage, T stage and neck lymph node metastasis) than a low-expression group. Conclusions: In this study, our experimental results in vitro were supported by clinical research. These findings suggest that TRIM32 is a novel oncogene that promotes tumor growth, metastasis and resistance to anti-cancer drugs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4047. doi:10.1158/1538-7445.AM2011-4047
AB0195 To develop a regression model for predicting damage-related haq: a nationwide study based on the ninja (national database of rheumatic diseases by ir-net in japan) 2011
Authors: S. Nishiyama, K. Ohashi, T. Aita, Y. Yoshinaga, S. Miyawaki, J. Nishino, S. Tohma
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> HAQ is one of evaluation methods for physical function and is thought to consist of activity HAQ (ACT_HAQ) and damage-related HAQ (DAM_HAQ)<sup>1</sup>. <h3>Objectives</h3> To search for important factors of ΔDAM_HAQ and to develop a regression model for predicting DAM_HAQ in patients with rheumatoid arthritis (RA). <h3>Methods</h3> Data of RA patients excluding surgical case were extracted from <i>NinJa</i>, an annually updated nationwide database in Japan. Correlation between ΔHAQ and ΔSDAI was calculated using 177 early RA patients (stage I and disease duration ≤1 yr) who were registered both 2010 and 2011, where ΔHAQ was approximately equal to ΔACT_HAQ. The result was ΔACT_HAQ/ΔSDAI≈ΔHAQ/ΔSDAI=0.0235. According to previous report<sup>1</sup>, we calculated ACT_HAQ=ΔACT_HAQ/ΔSDAI×SDAI=0.0235×SDAI, and DAM_HAQ=HAQ-ACT_HAQ using data of 2193 patients. Multiple regression analysis was performed to obtain a regression model for predicting ΔDAM_HAQ<sub>[2010,2011]</sub> (=DAM_HAQ<sub>2011</sub>-DAM_HAQ<sub>2010</sub>). The model was validated using 844 sequentially registered data from 2006 to 2011. <h3>Results</h3> ΔDAM_HAQ did not differ between male and female patients. Significant high ΔDAM_HAQ was observed in patients with older, longer disease duration, progressive stage and class, higher TJC28 and SJC28, larger VAS of physician and patient assessment, and high level of CRP. MTX users and boolean remission achievers had significant low ΔDAM_HAQ. Multiple regression analysis revealed that age, stage, class, TJC28, SJC28, patient assessment, CRP, MTX user or not, and boolean remission state were effective predictors for ΔDAM_HAQ. While DAM_HAQ<sub>2006</sub>+Σpredicted ΔDAM_HAQ<sub>[t, t+1]</sub> where t=2006 to 2010 (A) was overestimated DAM_HAQ<sub>2011</sub>, DAM_HAQ<sub>2006</sub>+Σ10% predicted ΔDAM_HAQ<sub>[t, t+1]</sub> (B) showed close correlation with DAM_HAQ<sub>2011</sub> (figure). <h3>Image/graph</h3> <h3>Conclusions</h3> ΔDAM_HAQ was affected by age, stage, class, TJC28, SJC28, patient assessment, CRP, MTX user or not, and boolean remission. One tenth of predicted ΔDAM_HAQ may be irreversible and accumulated on the former DAM_HAQ. <h3>References</h3> Smolen JS, et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. ARD 2010;69:1058-64. <h3>Disclosure of Interest</h3> None Declared
EFFECTS OF EXENATIDE ON CARDIAC FUNCTION, PERFUSION, AND ENERGETICS IN TYPE 2 DIABETIC PATIENTS WITH CARDIOMYOPATHY: A RANDOMIZED CONTROLLED TRIAL AGAINST INSULIN GLARGINE
Authors: Weena Jing Yan Chen, Michaela Diamant, Karin de Boer, Hendrik Harms, Lourens Robbers, Albert van Rossum, Mark Kramer, Adriaan Lammertsma, Paul Knaapen
Journal: Journal of the American College of Cardiology (2016)
SP0106 Motivational interviewing and self-regulation to increase physical activity in patients with rheumatoid arthritis
Authors: E. Hurkmans
Journal: Annals of the Rheumatic Diseases (2013)

So far, a number of studies have shown that interventions which are specifically aimed at promoting daily physical activity in patients with rheumatoid arthritis (RA) have positive effects on patients’ physical activity behaviour. However, in many studies it was found that patients relapse in their old sedentary behaviour within 3 months after the programme. Self-determination theory states that patient’s motivation and self-regulation skills are important aspects for behavior change. Examples of self-regulation skills are: setting realistic goals, self-monitoring and self-rewarding. One intervention that targets to increase patient’s autonomous regulation is Motivational Interviewing. One intervention that targets patient’s self-regulation skills is Self-regulation coaching. In 2011 a 5-week combined intervention that targeted both the motivation and self-regulation skills was performed to increase physical activity in the short- and long-term among insufficiently active patients with RA. In this trial seventy-eight patients with RA were randomly allocated to receive a group-based patient education session (control), or the education session plus a motivational interview and 2 self-regulation coaching sessions (MI+SR). Patients filled-in questionnaires at baseline, 6-weeks and 32-weeks follow-up. It was found that at 6-weeks, 67% and 23% of the MI+SR and control groups met the 5 x 30 recommendation for healthy physical activity. At 32 weeks, these percentages were 48% and 25%, respectively. Based on these results it can be concluded that this minimally resource-intensive intervention combining motivational interviewing and self-regulation coaching is an effective intervention to increase physical activity levels in patients with RA. And therefore clinicians should emphasize patients’ personal motivations and skills when promoting physical activity among patients with RA. <h3>Disclosure of Interest</h3> None Declared